MTOR and diabetes mellitus: The inhibition of the mammalian target of rapamycin (mTOR) pathway with rapamycin (RAPA, mTOR inhibitor) has shown promising results in controlling diabetes-induced detrimental effects during acute myocardial I/R injury [5,6,7].